Tokyo Tape
Sign in
← Sapporo Clinical Laboratory

Quarterly report · Q2

9776.TEDINET S100PECX
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥10.0bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥19.1bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥493m2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥777m2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥589m2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥1.6bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥821m2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥508m2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥717m2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥258m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥1.0bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥458m2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥319m2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥457m2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥16.2bnat 2022-09-30Cons.Assets
Total assets¥16.1bnat 2022-03-31Cons.Assets
Total assets¥15.3bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥5.7bnat 2022-09-30Cons.Liabilities
Total liabilities¥5.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥10.5bnat 2022-09-30Cons.Net assets
Net assets / equity¥10.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥9.8bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥3.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.0bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥2.4bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥674m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥1.6bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.0bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow¥292m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥831m2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥430m2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥223m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥113m2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥36m2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥77.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥54.092022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥306.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥134.132021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥102.972021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio63.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio62.8%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 44
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥46m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥44m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥2m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥30m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.2bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥371m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥356m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥805m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥472m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥333m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2022-04-01 → 2022-09-30−¥6m
—segment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥333m
—segment totalsegment profit2022-04-01 → 2022-09-30¥721m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥10.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥334m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥751m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥52m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥52m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥537,000
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥36m
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥3.8bn
jpcrp040300-q2r_E04950-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥580m
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥5.2bn
jpcrp040300-q2r_E04950-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥411m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue2021-04-01 → 2021-09-30¥1.3bn
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue external2021-04-01 → 2021-09-30¥532m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥754m
jpcrp040300-q2r_E04950-000Medical Devices And Maintenance Businessreportable segmentsegment profit2021-04-01 → 2021-09-30¥13m
—segment totalrevenue2021-04-01 → 2021-09-30¥10.3bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥9.5bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥754m
—segment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2021-04-01 → 2021-09-30¥755m
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥1.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 538
ItemContextValueUnit
Other ioaPrior1YearInstant235146000JPY
Other ioaCurrentQuarterInstant222832000JPY
Allowance for doubtful accounts ioa by groupPrior1YearInstant-16841000JPY
Allowance for doubtful accounts ioa by groupCurrentQuarterInstant-16841000JPY
Investments and other assetsPrior1YearInstant731974000JPY
Investments and other assetsCurrentQuarterInstant708559000JPY
Noncurrent assetsPrior1YearInstant8919805000JPY
Noncurrent assetsCurrentQuarterInstant8782049000JPY
AssetsPrior1YearInstant16149449000JPY
AssetsCurrentQuarterInstant16234132000JPY
Notes and accounts payable tradePrior1YearInstant2258565000JPY
Notes and accounts payable tradeCurrentQuarterInstant2113908000JPY
Current portion of long term loans payablePrior1YearInstant133692000JPY
Current portion of long term loans payableCurrentQuarterInstant133692000JPY
Lease obligations clPrior1YearInstant106041000JPY
Lease obligations clCurrentQuarterInstant115116000JPY
Income taxes payablePrior1YearInstant294056000JPY
Income taxes payableCurrentQuarterInstant216817000JPY
Provision for bonusesPrior1YearInstant120975000JPY
Provision for bonusesCurrentQuarterInstant256829000JPY
Accounts payable otherPrior1YearInstant125075000JPY
Accounts payable otherCurrentQuarterInstant206756000JPY
Asset retirement obligations clPrior1YearInstant28000000JPY
Asset retirement obligations clCurrentQuarterInstant－JPY
Other clPrior1YearInstant215389000JPY
Other clCurrentQuarterInstant231942000JPY
Current liabilitiesPrior1YearInstant3281795000JPY
Current liabilitiesCurrentQuarterInstant3275062000JPY
Long term loans payablePrior1YearInstant1732321000JPY
Long term loans payableCurrentQuarterInstant1665475000JPY
Lease obligations nclPrior1YearInstant610978000JPY
Lease obligations nclCurrentQuarterInstant568901000JPY
Provision for directors retirement benefitsPrior1YearInstant66870000JPY
Provision for directors retirement benefitsCurrentQuarterInstant64658000JPY
Net defined benefit liabilityPrior1YearInstant16107000JPY
Net defined benefit liabilityCurrentQuarterInstant17286000JPY
Long term accounts payable otherPrior1YearInstant97363000JPY
Long term accounts payable otherCurrentQuarterInstant93024000JPY
Other nclPrior1YearInstant6053000JPY
Other nclCurrentQuarterInstant5993000JPY
Noncurrent liabilitiesPrior1YearInstant2529694000JPY
Noncurrent liabilitiesCurrentQuarterInstant2415339000JPY
LiabilitiesPrior1YearInstant5811490000JPY
LiabilitiesCurrentQuarterInstant5690401000JPY
Capital stockPrior1YearInstant983350000JPY
Capital stockCurrentQuarterInstant983350000JPY
Capital surplusPrior1YearInstant1015270000JPY
Capital surplusCurrentQuarterInstant1015270000JPY
Retained earningsPrior1YearInstant8812690000JPY
Retained earningsCurrentQuarterInstant8993847000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass